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Abstract: Eleven 31-methylenlanostane triterpenoids, i.e., seven 21- and four 
26-oic acids, as well as a lupane triterpenoid betulin, isolated from the fruiting 
bodies of the mushroom Fomitopsis betulina, were tested for in vitro protective 
effect on chromosome aberrations in peripheral human lymphocytes using 
cytochalasin-B blocked micronucleus (CBMN) assay. Most of the tested com-
pounds showed a beneficial effect by reducing DNA damage of human lym-
phocytes more effectively than amifostine, a radioprotective agent, used as a 
positive control. All the tested compounds decreased MN frequency in the con-
centration dependent manner, with the concentration of 2.0 µg mL-1 being the 
most effective – with increase of the concentration the activity slightly dec-
reases. The structure–activity relationship (SAR) studies indicated that the 
lanostanes containing a conjugated 7,9 (11)-diene system exhibit lower activity 
than Δ8-analogues. It was also demonstrated that the DNA protective activities 
within the Δ8-lanostane-26-oic acid group are affected by the substitution in 
position 3 pattern. In the Δ8 series the oxygenation at C-12 or 16 as well as 21- 
or 26-oic acid functionality proved beneficial for in vitro protective effect on 
chromosomal aberrations. Betulin exhibited the lowest protective activity, but 
it is still comparable to that of amifostine. 
Keywords: lanostane triterpenoid derivatives; CBMN assey; micronucleus; 
Fomitopsis betulina. 
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INTRODUCTION 
Lanostanes are a group of triterpenoids present in a large number of medi-
cinal fungi such us Ganoderma lucidum,1 Gloeophyllum odoratum2 as well as 
other related fungi, Poria cocos,3 Laetiporus sulphureus, Inonotus obliquus, 
Antrodia camphorate, Daedalea dickinsii, Elfvingia applamata,4 Fomitopsis 
pinicola,5 Fomitopsis betulina,6 etc. Many lanostanes have shown great potential 
as anticancer agents owing to their cytotoxic and apoptotic effects on various 
cancer cell lines (Meth-A and LLC;7 K562,8 HepG2, Huh7 and Hep3B;4 HL-60;6 
THP-1,7 etc.). To the best of our knowledge, in vitro protective effect of lano-
stanes on chromosomal aberrations was only tested by Mata et al.9 on some iso-
lated from Euphorbia conspicua. Continuing our examination on wild growing F. 
betulina as a potential source of biologically active compounds,6 we now report 
the evaluation of DNA protective activity of the lanostanes 1–12 (Scheme 1). 
 
Scheme 1. Tested compounds 1–12. 
The cytokinesis-block micronucleus assay (CBMN) used in this study is a 
standard method for determining the safety of chemicals and pharmaceuticals. 
The result of the assay, measuring micronuclei (MN) in cultured human and/or 
mammalian cells, is specifically restricted to once-divided BN cells, which can 
express MN.10,11 Binuclear cells are formed when the dividing cells are treated 
with cytochalasin-B (Cyt-B), a blocker of cytokinesis that strongly inhibit the 
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ring assembling formation by actin filaments required for the end of cytokin-
esis.10–12 The MN may originate from acentric chromosome fragments, chromo-
some loss or a budding process following exposure to γ-irradiation.13 In their 
study, Ye et al.14 showed that the MN originate from the multiple broken ana-
phase bridges, although whether this actually happens or not, in cytokinesis- 
-blocked cells, remains unclear. The application of CBMN assay for the anti-
oxidant evaluation of heterocyclic compounds is well known.15–18 Hitherto, the 
antioxidant capacity of lanostanes is questionable and depends on the applied 
test.19,20 A potential of the lanostanes as DNA protecting agents, as well as the 
possible mechanism of their action is discussed. 
EXPERIMENTAL 
Two aliquots of venous blood, 5 ml each were obtained using heparinized sterile vacu-
tainers (Becton Dickinson, Bradford, MA). Six healthy non/smoking male volunteers who had 
not been exposed to chemicals, drugs or other substances gave their permission for using their 
blood in the experiment. A safety protocol concerning blood/born pathogen/biohazard was 
applied. The study complied with the code of ethics of the World Medical Association (Hel-
sinki Declaration of 1964, as revised in 2002).21 The blood samples were obtained at the 
Medical Unit in accordance with current Health and Ethical regulations in Serbia, Law on 
Health Care (2005).22 
Lanostanes 1–16 were isolated and purified as described.6 The culture lymphocytes were 
treated with three concentrations (1, 2, and 4 μg mL-1) of tested compounds. One cell culture 
served as the control and the tested chemical was not added in it. Amifostine WR-2721 (Mar-
ligen-Biosciences, USA), 1 µg mL-1, was used as a positive control and MMC (0.2 µg mL-1, 
in phosphate buffer) as a negative control.  
The treatment of binucleated (BN) cells with the examined compounds was carried out 
using the modified original procedure,23-25 applied previously applied in our laboratory.15,26 
At least 1000 BN cells per sample were scored, registering MN according to the criteria of 
Countryman and Heddle25 and Fenech and Morley.23  
The effects of investigated complexes on cell proliferation were estimated by the cyto-
kinesis-block proliferation index (CBPI), calculated as suggested by Surralles and others.27,28 
CBPI was calculated as:  
 CBPI = [(MI + 2MII + 3(MIII + MIV))]/N  (1) 
where MI–MIV represent the number of cells with 1 to 4 nuclei, respectively, and M is the 
number of cells scored. For the analysis of MNi, only binucleated cells with well-preserved 
cytoplasm were scored (under a light microscope with a 40 and 100 magnification). The 
criteria for selection of BN cells and the identification of MNi given in the HUMAN project 
website (http://www.humn.org) were followed.11 The number of BN cells with 1, 2, 3 or more 
MN were classified then. The data for each treatment were expressed as the frequency of MN 
per 1000 BN cells. 
The statistical analysis was performed using Origin software package version 7.0. The 
statistical significance of difference between the data pairs was evaluated by analysis of vari-
ance (One-way ANOVA) followed by the Tukey test. Statistical difference was considered 
significant at p < 0.01. 
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RESULTS AND DISCUSSION 
The tested compounds were isolated in our previous research.6 The identific-
ation was based on 1D and 2D NMR and HRESIMS spectra and their compar-
ison with the literature data (for NMR data see Supplementary material to this 
paper, Tables S-I–S-IV). Tested compounds were: pachymic acid (1),29 poly-
porenic acid G (2),6 polyporenic acid F (3),6 polyporenic acid C (4),30 piptolinic 
acid B (5),8 3-epi-dehydropachymic acid (6),8 polyporenic acid A (7),31 fomef-
ficinic acid A (8),32 12α-hydroxy-3α-(3′-hydroxy-4′-methoxycarbonyl-3′-methyl-
butyryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid (9),31 betulin (10),32 3α-
(acetyloxy)-16α-hydroxy-24-methylene-lanost-8-en-21-oic acid (11)33 and 
dehydropachymic acid (12).34 
All the compounds tested displayed a beneficial effect on the control lym-
phocyte cells giving a significant decrease of the frequency of MN in comparison 
with the control cell cultures (Fig. 1). According to the cytokinesis-block proli-
feration index (CBPI), routinely used to determine cytotoxicity of examined 
compounds in the in vitro MN test,23 the tested compounds did not show any sta-
tistically significant decrease. The comparable CBPI values for the investigated 
compounds and tests with positive or negative control suggested an inhibitory 
effect on the lymphocyte cell proliferation of tested compounds (Table S-V, Sup-
plementary material). The treatment of lymphocyte cells culture was carried out 
with mitomicyn C (MMC), a clastogenic agent that has been used to study the 
susceptibility of cell to chromosomal damage and cytotoxic effects.14 MMC is 
capable of inducing chromosome aberrations in vitro,35 DNA damage and MN.36 
 
Fig. 1. Decrease of MN frequency in computation to the control (see Table S-V, 
Supplementary material), effected by lanostane triterpenes 1-12. 
During this experiment, we analyzed 126,000 BN cells. Our results provide 
the evidence of the protective effect of the all tested lanostanes on cytogenetic 
potential and the reduction of damage on human lymphocytes treated in vitro. It 
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was also found that the tested compounds reduced the frequency of MN in con-
centration dependent manner, with the medium concentration of 2.0 µg mL–1 
being the most effective (Fig. 1). 
Since MN expression is dependent on cell division, the quantification of cell 
proliferation and cell death is the best way to obtain reliable results is evaluation 
of cell kinetics and MN frequencies. Among the tested compounds at concen-
trations of 1, 2, and 4 μg mL–1, compound 2 exhibits the most prominent effect 
of decreasing the (p < 0.01) frequency of MN by 37, 44 and 40 %, respectively, 
when compared with the control cell cultures. A somewhat smaller effect was 
shown for compounds 1, 3 and 9 at the same concentrations, decreasing the (p < 
0.01) frequency of MN by 33, 39, 36; 30, 35, 32; 35, 38 and 36 %, respectively, 
when compared with the control cell cultures (Table S-V, Supplementary mat-
erial). The compounds 4, 10 and 12 at all tested concentrations caused decrease 
of the MN frequency in the range similar to that of amifostine, a radioprotective 
compound. Owing to selective action of amifostine on healthy tissues and its 
anti-mutagenic and anti-carcinogenic properties, it was used as a drug on onco-
logy patients, against the damaging effects of radiation and chemotherapy.37 All 
the compounds tested showed the highest activity at the concentration of 2 μg 
mL–1 – with an increase of the concentration the activity slightly decreases, 
which was not the case with the previously studied jatrophanes and sesquiterpene 
lactones (Krstić et al.17 and Cvetković et al.18, respectively). The typical DNA 
protective activity of natural products is mostly attributed to their antioxidative 
potential.15–18 The cytotoxic and antioxidant activity of nine lanostane-type tri-
terpenes, isolated from P. cocos, were examined previously by Zhou et al.20 
They tested the ability of scavenging free oxygen radicals and inhibition of oxid-
ation using 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical test. In comparison to 
the vitamin E used as a positive control, the compounds tested did not show anti-
oxidant activity with p < 0.05 that may be considered statistically significant. On 
the other hand, Sekiya et al.19 carried out the free radical-induced lyses using 
2,2-azo-bis(2-amidinopropane) dihydrochloride (AAPH) of human red blood 
cells, in order to investigate anti-hemolytic activity of triterpenes isolated from 
Hoelen, sclederma of P. cocos. They found that lanostane triterpene carboxylic 
acids isolated from the methanol extract of Hoelen, i.e., pachymic acid, poly-
porenic acid, 3-epidehydrotumulosic acid, 3β-hydroxylanosta-7,9(11), 24-trien- 
-21-oic acid and 3-O-acetyl-16-α-hydroxytrametenolic acid, exhibited inhibitory 
activities against AAPH-induced lyses of red blood cells. Whereas in the first 
study,20 stabile free radicals were used. In the second investigation free radicals 
were induced by AAPH thermal decomposition in aqueous conditions. Sekiya et 
al.19 measured AAPH-induced hemolysis at 540 nm which, according to Nuruki 
et al.38 was not the optimal wavelength, because AAPH oxidizes the oxygenated 
hemoglobin to methemoglobin and absorbance at 540 nm does not correctly ref-
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lect the amount of released hemoglobin by AAPH-induced hemolysis. Thus, the 
absorbance at 523 nm correctly reflects the amount of released hemoglobin reg-
ardless of the status of hemoglobin (isosbestic point).38 
Generally, the compounds 4, 6 and 12 containing a conjugated 7,9 (11)- 
-diene system exhibited lower activity than the Δ8-analogues 1–3, 7–9 and 11. At 
the same time, compared to Δ8-lanostanes,6 the conjugated 7,9 (11)-diene system 
has a positive effect on cytotoxicity to HL 60 cells.6 It was also shown that the 
DNA protective activities within the Δ8-lanostane-26-oic acid group (2, 3, 7 and 
9) (Fig. 1) are affected by the substitution in position 3 pattern. Thus, 3-keto 
lanostane 2, showed slightly higher activity than those bearing 3-hydroxy (7) or 
3-O-acyl substituents (3 and 9). Moreover, in the Δ8-lanostane-21-oic acid series 
(1 and 11), the DNA protection activity was dependent on the configuration at 
C-3. Lanostane 1 with the acetoxy group in 3β-position revealed significantly 
higher activity than the epimeric 3α-acetoxy lanostane 11 (Fig. 1). It should be 
noted that the compound 1 also exhibited higher cytotoxic activity in comparison 
with 11.6 
In the Δ8 series the oxygenation at C-12 or 16 as well as 21- or 26-oic acid 
functionality were shown beneficial for in vitro protective effect on chromosomal 
aberrations. The smallest activity among the tested compounds was observed for 
compound 10, botulin. This pentacyclic compound, lacking these functionalities, 
decreased the frequency of MN to the same extent as amifostine. Compound 5 
has an open (3,4-seco) A ring and the rest of the skeleton is the same as in com-
pound 8. Both compounds have shown the same effect on NB cells so the scis-
sion of ring A showed no activity effect.  
The above results indicate that the mechanism of action, as DNA protective 
agents, is not based on the antioxidant potential of tested compounds. Some other 
biochemical process, regulated by enzymes, should be considered as the mech-
anism of their action. Zhang et al.39 tested inhibitory effects of triterpene inoto-
diol, the constituent of the fungus I. obliquus, commonly known as “chaga” on 
HeLa cells migration, invasion and induction of apoptosis. The results of West-
ern blot analysis demonstrated that inotodiol could activate p53 and p21 proteins 
expression. The p 53 protein is crucial in the regulation of the cell cycle and, 
depending on the level of DNA damage, stops the G1 phase and activates repair 
mechanisms, increasing the expression of p21, or conduct cell into apoptosis. 
Protein p21, the cyclin-dependent kinase inhibitor located downstream of p53 
gene, is closely related to tumor inhibition.440 
We believe that tested lanostanes have similar regulatory mechanism on cell 
cycle regulating the p53 exertion however, this needs further investigation.  
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CONCLUSION 
This paper presents a study of the influence of twelve triterpenes on cytoge-
netic potential and reduction of damage on human lymphocytes treated in vitro.  
According to the cytokinesis-block proliferation index (CBPI), all the com-
pounds tested exerted a significant decrease of the MN frequency in comparison 
with the control cell cultures. At the same time, the tested compounds did not 
show statistically significant cytotoxicity. The highest DNA protective activity 
was at concentration of 2 μg mL–1, whereas at the higher concentration (4 μg 
mL–1), the activity slightly decreased. The best results were obtained with poly-
porenic acid G (2), Δ8-lanostane-26-oic acid with 3-keto group. The oxygenation 
at C-12 or 16 as well as 21- or 26-oic acid functionality were beneficial for in 
vitro protective effect on chromosomal aberrations. The comparison of our 
results with the literature data indicated the tested lanostanes effects on cell cycle 
regulating the p53 exertion which require further investigation. 
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И З В О Д  
ДНК ПРОТЕКТИВНА АКТИВНОСТ ТРИТЕРПЕНА ИЗОЛОВАНИХ ИЗ МЕДИЦИНСКЕ 
ГЉИВЕ Fomitopsis betulina 
ИВАНА В. СОФРЕНИЋ1, БОБАН Д. АНЂЕЛКОВИЋ1, ЉУБОДРАГ В. ВУЈИСИЋ1, МИРОСЛАВ М. НОВАКОВИЋ2, 
АЛЕКСАНДАР З. КНЕЖЕВИЋ3, МИРОСЛАВА Б СТАНКОВИЋ4, СЛОБОДАН М. МИЛОСАВЉЕВИЋ1,5 
и ВЕЛЕ В. ТЕШЕВИЋ1 
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Београду, Институт за хемију технологију и металургију, Институт од националног значаја за 
Републику Србију, Његошева 12, 11000, Београд, 3Универзитет у Београду, Биолишки факултет, 
Таковска 43, 11000, Београд, 4Нуклеарни објекти Србије, Мике Петровића Аласа 12-14, 11351, Винча 
и 5Српска академија наука и уметности, Кнез Михајлова 35, 11000, Београд 
Једанаест 31-метиленланостанских тритерпеноида, то јест седам 21- и четири 26-
ланостанских киселина, као и лупански тритерпеноид бетулин изолованих из плодонос-
них тела гљиве Fomitopsis betulina тестирани су in vitro на заштитни ефекат на аберације 
хромозома у периферним хуманим лимфоцитима. Примењен је тест мерења учес-
талости микронуклеуса индукованих применом инхибитора цитокинезе, цитохалазина 
Б. Испитивања су показала да већина тестираних једињења показује значајан протек-
тивни ефекат на ДНК хуманих лимфоцита, већи него комерцијални радиопротективни 
агенс аминофостин. У опсегу концентрација 1, 2 и 4 μg mL-1 сва испитивана једињења су 
смањивала учесталост микронуклеуса (MN), при чему је најефиканија била концентра-
ција од 2,0 μg mL-1. Са повећањем концентрације (4 μg mL-1) активност се благо смањује. 
Студије односа структуре и активности (SAR) показале су да ланостани који садрже кон-
југовани 7,9-(11)-диенски систем имају нижу активност од 8-аналога. Такође је пока-
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зано да на заштитне активности ДНК унутар групе 8-ланостан-26-киселина утиче суп-
ституција у положају 3. У 8-серији присуство кисеоничних функција на C-12 или C-16, 
као и C-21 или C-26 карбоксилних група повећава in vitro протективни ефекат на на 
ДНК хуманих лимфоцита. Међу испитиваним једињењима тритерпен бетулин (лупанска 
серија) је показао најмањи протективни ефекат сличан са протективним ефектом ами-
фостина. 
(Примљено 1. априла, ревидирано 20. маја, прихваћено 24.маја 2021) 
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